# BPC-157 Dosage Research — Animal Study Doses, Routes, and Pharmacokinetics

> Research-context overview of BPC-157 doses studied in animal models, pharmacokinetics (half-life, bioavailability, distribution), and routes of administration studied. Not dosing guidance for human use.

What the pharmacokinetic studies say about how BPC-157 moves through a body — and why that complicates the obvious interpretation.

## The short version

The doses used in BPC-157 animal studies typically range from 10 nanograms per kilogram to 200 micrograms per kilogram — a very wide band, and one where even the lowest doses appear active in several models. This page describes those research doses for readers who want to understand the published studies, not as a guide to human use. BPC-157 has a measured plasma half-life of under 30 minutes in rats and dogs, which raises a mechanistic puzzle: how does a compound that clears the bloodstream so quickly produce healing effects that last weeks? The answer is not settled. Routes studied include intraperitoneal, intramuscular, intravenous, oral, topical, and intravesicular — an unusually broad range for a single research compound.

## A note on framing: this is research context, not dosing guidance

BPC-157 is not FDA-approved for any human indication. The content below describes the doses used in published animal studies — the concentrations, routes, and schedules that researchers employed in preclinical models. This information is provided to help readers understand the research literature, not to suggest what a human should take or how. The distinction is not a legal formality: animal doses do not translate directly to human doses, and body weight scaling, metabolic differences, and species-specific biology all introduce substantial uncertainty into any cross-species extrapolation.

The compounding pharmacy route for BPC-157 in the United States has been legally restricted. As of this writing, BPC-157 is not on the FDA's 503A Category 1 Bulks List (permitted for compounding) and was removed from Category 2 (prohibited for compounding) in April 2026 after the original nomination was formally withdrawn. It currently occupies regulatory limbo. A Pharmacy Compounding Advisory Committee (PCAC) meeting to evaluate BPC-157 for potential 503A Category 1 inclusion is scheduled for July 23–24, 2026. Nothing in this page should be read as guidance on obtaining, administering, or compounding BPC-157 for any use. The dosage section below is a summary of what animal studies used.

## Doses used in preclinical research

Across the published BPC-157 literature, the dose range studied in rodent models spans multiple orders of magnitude — from 200 ng/kg (nanogram range) to 200 μg/kg (microgram range), with the most commonly used dose in healing studies being 10 μg/kg intraperitoneally [4] [6] [15]. The observation that nanogram-range doses (10 ng/kg) appear active in multiple ligament, tendon, and quadriceps reattachment models is one of the more unusual features of the literature — compounds active in the nanogram-per-kilogram range are rare and the mechanism of that potency is not explained by current published data [5] [6].

Specific dose examples from published studies:

- **Ligament healing (medial collateral ligament, rat):** 10 μg/kg or 10 ng/kg intraperitoneal daily; 1.0 μg/g neutral cream topical [6]
- **Muscle crush injury (rat):** 10 μg/kg intraperitoneal or topical thin cream layer [15]
- **Gastric ulcer protection (rat):** 200, 400, and 800 ng/kg intramuscular or intragastric [7]
- **Bone defect healing (rabbit):** 10 μg/kg or 10 ng/kg percutaneous local injection, intramuscular intermittent or continuous [16]
- **Colitis and ischemia-reperfusion (rat):** 10 μg/kg topical bath, per-oral drinking water, or intraperitoneal [8]
- **Spinal cord compression (rat):** 200 μg/kg or 2 μg/kg single intraperitoneal injection administered 10 minutes post-injury [9]
- **Ischemia-reperfusion organ protection (rat):** 20 μg/kg intraperitoneal [17]
- **Quadriceps muscle reattachment (rat):** 10 μg/kg or 10 ng/kg per-oral drinking water daily [5]
- **Regional serotonin synthesis modulation (rat brain):** 10 μg/kg intraperitoneal acute and 7-day repeated [14]
- **In vitro tendon fibroblast GH receptor upregulation:** 0.1, 0.25, and 0.5 μg/mL cell culture [13]

The spinal cord compression study used the highest single dose in the literature — 200 μg/kg intraperitoneally — as one of its test arms, and observed equivalent functional benefit at the 2 μg/kg arm [9]. The dose-equivalence across a 100-fold range in that particular model suggests either that the receptor target (or targets) saturate at very low concentrations, or that the functional outcome measure was insufficiently sensitive to distinguish dose-response relationships. Both interpretations are consistent with the data.

## Routes of administration studied

One of the features of the BPC-157 preclinical literature is the breadth of routes across which active effects have been documented. Most research peptides show meaningful activity only parenterally; oral bioavailability in humans is typically negligible for compounds above approximately 500 daltons. BPC-157 at 1,419.5 daltons is well above that threshold, which is why its gastric stability and oral activity in rodent models attract attention — even as a direct translation to human oral bioavailability remains unproven.

Routes studied in published literature include: intraperitoneal (the most common in preclinical rodent studies), per-oral gavage and drinking water, intramuscular, subcutaneous, intravenous (pharmacokinetic studies and IRB-approved human pilot), topical cream (thin layer at injury site), local bath application (ischemia-reperfusion models), intragastric, intra-articular (human retrospective case series), and intravesicular (human interstitial cystitis pilot) [4].

Several findings in the oral route literature are methodologically important. In the quadriceps reattachment study, the initial dose was delivered intragastrically 5 minutes post-surgery, and subsequent daily doses were administered via drinking water — the rats drank their dose as part of normal water intake [5]. The volume consumed was approximately 12 mL per rat per day at concentrations of 0.16 μg/mL or 0.16 ng/mL [8]. That the compound reached and healed the surgical site via this route — and that it did so comparably at concentrations 1,000-fold apart — is the finding that makes the gastric stability data meaningful rather than merely pharmacologically interesting.

## Pharmacokinetics: half-life, bioavailability, distribution, and metabolism

The definitive pharmacokinetic characterization of BPC-157 was published in 2022 by He et al. in Frontiers in Pharmacology, using both rat and beagle dog models [1]. The study measured plasma half-life, Tmax, intramuscular bioavailability, organ distribution, urinary and biliary recovery, and metabolites across multiple IV and IM dose levels.

Key findings:

- **Plasma half-life:** Under 30 minutes in both species following IV and IM administration
- **Tmax:** 3 minutes in rat (IV); 6.3–8.7 minutes in dog (IM)
- **Intramuscular bioavailability:** 14–19% in rat; 45–51% in beagle dog
- **Organ distribution:** Highest concentration in kidney (560 ng/mL at 1 hour), followed by liver
- **Urinary recovery:** approximately 16–18%
- **Biliary recovery:** approximately 9%
- **Metabolism:** Hepatic; primary metabolite is proline plus small peptide fragments
- **PK kinetics:** Linear across doses tested

The sub-30-minute plasma half-life raises an immediate interpretive question: how does a compound with a plasma half-life shorter than most people's lunch break produce functional improvements sustained for weeks to months in preclinical models — including spasticity resolution maintained through day 360 after a single injection [9]? The research literature does not definitively answer this. Proposed mechanisms include tissue-level receptor interactions that persist beyond plasma clearance, local depot effects from extravascular distribution, and receptor-mediated changes in gene expression that outlast the compound's plasma presence. The pharmacokinetic data is real; the mechanistic reconciliation with the durability of preclinical effects is not yet established in the published literature.

The gastric stability data is worth noting alongside the PK data. BPC-157 is stable in human gastric juice for more than 24 hours [1]. For a peptide above 1,400 daltons, this is unusual and is the mechanistic basis for the oral and intragastric efficacy observed in rodent models. Whether this stability translates to sufficient oral bioavailability for pharmacological effect in humans — a species with different gastric transit times, enzyme concentrations, and intestinal surface area than a rat — is the key translational gap that the cancelled Phase I pharmacokinetics study (NCT02637284, registered 2015, cancelled 2016) would have addressed [3].

---

A literature digest drawn from peer-reviewed sources — not a clinic, not a vendor, not a prescription.